Latest Breaking News On - Novarti beovu - Page 2 : comparemela.com

Pyxis Oncology (PYXS) to Acquire Apexigen (APGN) for $0 64/sh

Pyxis Oncology (PYXS) to Acquire Apexigen (APGN) for $0 64/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWilson sonsini goodrich rosatiJan pinkasXiaodong yangJaym feingoldPamela connealyLaras sullivanNovarti beovuContactjennifer davis ruffviceApexigen contactwilliam dukechief financial officerapexigen incLadenburg thalmann coAmerican society of clinical oncologyApexigen incFlexible antibody conjugation technologyLegal advisors sidley austinPyxis oncology inc

Pyxis Oncology : to Acquire Apexigen - Form 8-K

Pyxis Oncology to Acquire Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate development Commercially and clinically validated APXiMAB. | May 24, 2023

United statesLaras sullivanWilliam dukeXiaodong yangWilson sonsini goodrich rosatiJaym feingoldNovarti beovuPamela connealyJan pinkasApexigen incPyxis oncology incAmerican society of clinical oncologySidley austinLadenburg thalmann coFlexible antibody conjugation technologyExchange commission

Adverum Slashes Workforce By 38%, Hones In On Eye Disease Candidate

Adverum Biotechnologies is cutting 78 jobs after announcing it had successfully amended its Investigational New Drug application for ADVM-022.to treat wet age-related macular degeneration.

United statesPascal bacheletLaurent fischerNovarti beovuRegeneron eyleaImages groupEuropean medicines agencyDrug administrationAdverum cutsHones in on eye diseaseUniversal images groupBiotechnologiesannounced thursdayInvestigational new drugPriority medicinesDverum slashes workforce by 38Ones in on eye disease candidate

Why Regeneron Investors Shouldn t Fear Its Patent Cliff

New treatments will step in to replace blockbuster eye medication EYLEA.

United statesRegeneron dupixentNovarti beovu

US FDA and EMA accept application for Novartis Beovu to treat DME

US FDA and EMA accept application for Novartis Beovu to treat DME
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.

Jill hopkinsNovarti beovuJapanese pharmaceuticalsEuropean medicines agencyEuropean commissionDrug administrationDevices agencyMedical devices agency